



USA Prime Labs
Substance Testing and COA
We test the research before you do.



www.usaprimelabs.com

CERTIFICATE OF ANALYSIS

Identity, purity and safety panel

Report No. UPL-2026-0205

Issued 2026-09-20

Page 1 of 1

SAMPLE

Compound **Semaglutide**
Form **Lyophilized powder**
Label claim **20 mg / vial**
Lot / batch **SE-3863**
Sample ID **UPL-2026-0205**
Vials received **5**

CLIENT AND CHAIN OF CUSTODY

Client **USA Prime Peptides**
Client reference **UPP-1400**
Received **2026-08-14**
Testing period **2026-09-05 to 2026-09-18**
Storage **2-8 °C**
Panel **Full panel**

TEST	METHOD	RESULT	SPECIFICATION	STATUS
Identity Chemistry	LC-MS	Conforms Observed [M+H] ⁺ consistent with theoretical	Matches reference	PASS
Purity Chemistry	HPLC-UV	98.69%	Report value	PASS
Net content Chemistry	Gravimetric	21.28 mg 106.4% of label claim	90 - 110 % of label claim	PASS
Water content Chemistry	Karl Fischer	6.91%	<= 10.0 %	PASS
Residual solvents Safety	GC-HS	Pass Acetonitrile 21 ppm; DMF not detected	Within ICH Q3C limits	PASS
Endotoxin Safety	LAL kinetic	0.34 EU/mg Spike recovery 117%	<= 1.0 EU/mg	PASS
Heavy metals Safety	ICP-MS	Pass As 0.138 · Cd 0.05 · Pb 0.043 · Hg 0.049 ug/g	As 1.5, Cd 0.2, Pb 0.5, Hg 0.3 ug/g	PASS
Bioburden Safety	USP <61>	TAMC <10 CFU/g TYMC <10 CFU/g	TAMC <= 100, TYMC <= 10 CFU/g	PASS
Sterility Safety	USP <71>	No growth	No growth	PASS

OVERALL: PASS All tests meet specification

98.69%

Jane Rivera

Analyst
Jane Rivera, Senior Analyst
Signed Sep 22, 2026

Dr. Mark Chen, MD

QA Reviewer
Mark Chen, QA Director
Approved Sep 22, 2026



Verify this certificate
Report UPL-2026-0205

For research use only. Not for human or veterinary use. This certificate reports analytical results and is not a claim about any product.